50 Landmark Papers every Breast Surgeon Should Know

Herausgeber: Cutress, Ramsey; Wyld, Lynda; Morgan, Jenna

• Broschiertes Buch

Produktbeschreibung

This book identifies 50 key scientific articles in the field of breast disease and surgery, examining their importance and impact. A valuable reference to the established surgeon, breast surgery residents and trainees.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• 50 Landmark Papers
• Verlag: Taylor & Francis Ltd
• Seitenzahl: 318
• Erscheinungstermin: 15. April 2024
• Englisch
• Abmessung: 229mm x 152mm x 17mm
• Gewicht: 474g
• ISBN-13: 9781032471273
• ISBN-10: 1032471271
• Artikelnr.: 69791632

Autorenporträt

Lynda Wyld is Professor of Surgical Oncology at the University of Sheffield and a Consultant Oncoplastic Surgeon at Doncaster and Bassetlaw Teaching Hospitals. She is the Past President of the British Association of Surgical Oncology (BASO) and Past Chair of the European Society of Surgical Oncology (ESSO) Education Committee and is a Trustee of the Association of Breast Surgery (ABS). Ramsey Cutress is Professor of Breast Surgery at University of Southampton and a Consultant Surgeon at University Hospital Southampton. He is Chair of the Association of Breast Surgery (ABS) Academic and Research Committee, Course Director for the ABS Advanced Skills in Breast Disease Management course, Head of the School for Clinical Academic Training at the Wessex Deanery and breast disease subspecialty editor for the Annals of the Royal College of Surgeons of England, demonstrating his interests in research and teaching. Jenna Morgan Jenna is an NIHR Advanced Fellow Breast Surgery at the University of Sheffield and a Consultant Oncoplastic Surgeon at the Jasmine Breast Unit in Doncaster, UK. She is Past Chair of the Mammary Fold Academic Committee of the ABS. She is a clinical academic with an interest in mixed methods research, geriatric oncology and the psychology or ageing in healthcare settings.

Inhaltsangabe

Section One: Epidemiology 1. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence Collaborative Group on Hormonal Factors in Breast Cancer 2. Moderate Alcohol Intake and Cancer Incidence in Women Allen N
Beral V
Cassabone D
Kan SW
Reeves GK
Brown A
Green J on behalf of the Million Women Study Collaborators Section Two: Screening and Prevention 3. 3. Tamoxifen for Prevention of Breast Cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study (NASBP P-1) Fisher B
Costantino J
Wickerman D
et al 4. 4. The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. Tabar L
Fagerberg G
Duffy SW
et al 5. 5. The benefits and harms of breast cancer screening: an independent review Marmot MG
Altman DG
Cameron DA
Dewar JA
Thompson SG
Wilcox M. Section Three: Diagnostic Imaging 6. 6. Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening (DMIST) Pisano ED
Gatsonis C
Hendrick E
Yaffe M
Baum JK
Acharyya S
Conant EF
Fajardo LL
Bassett L
D'Orsi C
Jong R
Rebner M 7. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) Leach MO
Boggis CRM
Dixon AK
Easton DF
et al 8. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial Turnbull L
Brown S
Harvey I
Olivier C
Drew P
Napp V
Hanby A
Brown J Section Four: Surgery: Mastectomy versus conservation 9. 9. Twenty-year follow-up of a randomized trial comparing total mastectomy
lumpectomy
and lumpectomy plus irradiation for the treatment of invasive breast cancer Fisher B
Anderson S
Bryant J
Margolese RG
Deutsch M
Fisher ER
Jeong JH
Wolmark N 10. The Association of Surgical Margins and Local Recurrence in Women with Early-Stage Invasive Breast Cancer Treated with Breast Conserving Therapy: A Meta-Analysis Houssami N
Macaskill P
Marinovich ML
Morrow M 11. Ten year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study van Maaren MC
de Munck L
de Back GH
Jobsen J
van Dalen T
Poortmans P
Strobbe LC
Siesling S. Section Five: De-escalation of Axillary Surgery 12. 12. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy
total mastectomy
and total mastectomy followed by irradiation. Fisher B
Jeong JH
Anderson S
Bryant J
Fisher ER
Wolmark N 13.13. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women with Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. Giuliano AE
Ballman KV
McCall L
et al. 14. 14. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised
multicentre
open-label
phase 3 non-inferiority trial. Donker M
van Tienhoven G
Straver ME
et al 1515. Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial Boughey JC
Suman VJ
Mittendorf EA
et al. Section Six: Oncoplastic Breast Surgery / Breast Reconstruction 16. 16. Planning and use of therapeutic mammaplasty-Nottingham approach S J McCulley and R D Macmillan 17.17. Oncoplastic breast¿conserving surgery for women with primary breast cancer Nanda A
Hu J
Hodgkinson S
Ali S
Rainsbury R
Roy PG. 18.18. Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre
prospective cohort study Potter et al 19.19. Improving Breast Cancer Surgery: A Classification and Quadrant per Quadrant Atlas for Oncoplastic Surgery Clough KB
Kaufman GJ
Nos C
Buccimazza I
Sarfati IM Section Seven: Breast cancer genomics and prognostic tools 20.20. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Therese Sørlie
Charles M. Perou
Robert Tibshirani
Turid Aas
Stephanie Geisler
Hilde Johnsen
et al. 21.21. Comprehensive molecular portraits of human breast tumours The cancer Genome Atlas Network 2222. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer Fatima Cardoso
Laura J. van't Veer
Jan Bogaerts
et al for the MINDACT investigators 23. 23. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (RxPonder) K. Kalinsky
W.E. Barlow
J.R. Gralow
et al 24.24. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer Gordon C Wishart
Elizabeth M Azzato
David C Greenberg
Jem Rashbass
Olive Kearins
Gill Lawrence
Carlos Caldas
and Paul DP Pharoah Section Eight: Ductal Carcinoma In Situ 25 25. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Esther H. Lips
Tapsi Kumar
Anargyros Megalios
Lindy L. Visser
Michael Sheinman
Angelo Fortunato
et al 26.26. Pathological features of 11
337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the Sloane Project Shaaban AM
Hilton B
Clements K
Provenzano E
Cheung S
Wallis MG
Sawyer ES
Thomas JS
Hanby AM
Pinder SE
Thompson AM 27. 27. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Cuzick J
Sestak I
Pinder SE
Ellis IO
Forsyth S
Bundred NJ
Forbes JF
Bishop H
Fentiman IS
George WD 28. 28. A prognostic index for ductal carcinoma in situ of the breast. Silverstein MJ
Poller D
Craig PH
et al Section Nine: Adjuvant Chemotherapy 29. 29. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100
000 women in 123 randomised trials Peto
R.
Davies
C.
Godwin
J.
Gray
R.
Pan
H. C.
Clarke
M.
Cutter
D.
Darby
S.
McGale
P.
Taylor
C.
Wang
Y. C.
Bergh
J.
Di Leo
A.
Albain
K.
Swain
S.
Piccart
M.
& Pritchard
K 30. 30. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. CREATE-X N Masuda
Soo-Jung Lee
S Ohtani
Y-H Im
E-S Lee
I Yokota
K Kuroi
S-A Im
B-W Park
S-B Kim
Y Yanagita
and S Ohno et al Section Ten: Adjuvant Endocrine Therapy 31. 31. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 32.32. Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor - positive breast cancer: ATLAS
a randomised trial C Davies et al 33. 33. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer Prudence A Francis et al 34.34. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial ATAC Trialist's Group Section Eleven: Immunotherapy / Systemic Therapy 35. 35. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Cameron D
Piccart-Gebhart MJ
Gelber RD
Procter M
Goldhirsch A
de Azambuja E
et al & Herceptin Adjuvant (HERA) Trial Study Team 36.36. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer Tutt ANJ
Garber JE
Kaufman B
et al 37.37. Pembrolizumab for Early Triple-Negative Breast Cancer Schmid
P.
et al 38.38. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer von Minckwitz
Huang
Mano
et al. for the KATHERINE Investigators Section Twelve: Adjuvant Radiotherapy 39.39. Breast-conserving surgery with or without irradiation in early breast cancer (PRIME II). Ian H Kunkler et al 40.40. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 41.41. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. H Bartelink et al 42.42. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 43.43. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects; results from a multicentre
non-inferiority
randomised
phase 3 trial. Brunt AM
et al Section Thirteen: Bisphosphonates 44.44. Zoledronic acid as adjuvant therapy for breast cancer (does Adjuvant Zoledronic acid redUce REcurrence in patients with high risk
localised breast cancer)
the AZURE trial Robert Coleman
David Cameron
David Dodwell
et al on behalf of the AZURE investigators. 45.45. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial Eastell
R.
Adams
J.
Clack
G.
Howell
A.
Cuzick
J.
Mackey
J.
Beckmann
M. W.
& Coleman
R. E. Section Fourteen: Surgery for Metastatic Disease 46. 46. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Rajendra Badwe
Rohini Hawaldar
Nita Nair
Rucha Kaushik
Vani Parmar
Shabina Siddique
Ashwini Budrukkar
Indraneel Mittra
Sudeep Gupta Section Fifteen: Breast Cancer in Pregnancy / Prophylactic surgery for family history 47.47.Treatment of breast cancer during pregnancy: an observational study Loibl S
Han SN
Minckwitz GV
Bontenbal M
Ring A
Giermek J et al 48.48. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study Ellen R Copson
Tom C Maishman
Will J Tapper
Ramsey I Cutress
Stephanie Greville-Heygate
Douglas G Altman et al 49.49. Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer. Hartmann L.
Schaid D.
Woods J.
Crotty T.
Myers J.
Arnold P.et al 50. 50. Wire- and magnetic-seed-guided localization of impalpable breast lesions: iBRA-NET localisation study (Arm 1) Rajiv V Dave
Emma Barrett
Jenna Morgan
et al on behalf of the iBRA-NET Localisation Study collaborative